Wells Fargo & Company Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $289.00

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) had its price target boosted by Wells Fargo & Company from $264.00 to $289.00 in a report issued on Tuesday morning, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biotechnology company's stock.

A number of other research firms have also commented on ASND. Evercore ISI lifted their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an outperform rating in a research report on Tuesday. Citigroup dropped their target price on shares of Ascendis Pharma A/S from $193.00 to $178.00 and set a buy rating on the stock in a research report on Wednesday, September 4th. Cantor Fitzgerald reaffirmed an overweight rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Monday. JPMorgan Chase & Co. dropped their target price on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an overweight rating on the stock in a research report on Wednesday, September 4th. Finally, Bank of America boosted their target price on shares of Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a buy rating in a research report on Wednesday, September 4th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of Moderate Buy and an average target price of $193.77.

Ascendis Pharma A/S Stock Up 5.0 %

Shares of NASDAQ:ASND traded up $7.02 during trading on Tuesday, reaching $146.59. The stock had a trading volume of 1,993,209 shares, compared to its average volume of 435,695. Ascendis Pharma A/S has a 52 week low of $85.29 and a 52 week high of $161.00. The firm has a market capitalization of $8.54 billion, a price-to-earnings ratio of -14.97 and a beta of 0.63. The stock has a fifty day simple moving average of $132.51 and a two-hundred day simple moving average of $136.47.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently bought and sold shares of ASND. Private Ocean LLC acquired a new stake in shares of Ascendis Pharma A/S in the 1st quarter valued at $36,000. GAMMA Investing LLC boosted its stake in shares of Ascendis Pharma A/S by 52.0% in the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 102 shares in the last quarter. Quadrant Capital Group LLC lifted its position in Ascendis Pharma A/S by 90.4% during the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock worth $40,000 after buying an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company's stock worth $42,000 after buying an additional 91 shares in the last quarter. Finally, Bessemer Group Inc. lifted its position in Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company's stock worth $132,000 after buying an additional 332 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.